#Advaxis (ADXS)

Advaxis Outperformed on a Negative Market Day ADXS Outperformed Advaxis’ (ADXS) stock rallied today as the U.S. Food and Drug Administration (FDA) lifted the partial clinical hold on its product AIM2C...

Advaxis (ADXS) is a small clinical-stage biotech producing and developing cancer immunotherapy products based on its proprietary Lm Technology. The technology uses bioengineered live attenuated Lister...

Investors in the stock market know that stocks yo-yo all the time. Sometimes, the yo-yoing becomes so severe it could trigger the soaring of some stocks and the tumbling of others. This article is abo...

Prohost Letter #393 IMMUNOTHERAPY -  PROHOST PORTFOLIO -  NEW PICKS? -  A Brief Reminder of the CAR T –TCR Immunotherapy Approaches In this issue we continue our journey inside the territory of cancer...

Prohost Letter #378 Part 2 2015 ASCO ANNUAL MEETING What a Big Revolution in Oncology! The ASCO meeting projected the huge advancement in the understanding, diagnosing and treating cancer. What looked...

Immunotherapy For Metastatic, Castration-Resistant Prostate Cancer This time the immunotherapy drugs combination for advanced prostate cancer are coming from Advaxis (ADXS) and Merck (MRK) , known as...

Prohost Letter #375 Part 1 BIOTECHNOLOGY: THE BEGINNING OF A NEW ERA STATE- OF-THE-ART APPROACHES FOR  THE MANAGEMENT OF CHRONIC AND DEADLY DISEASES  ARE IN HUMAN CLINICAL TRIALS We are encouraged by...